At the J.P. Morgan Healthcare Conference, Coherus Outlines "Branded Approach" to Biosimilars
January 8th 2019
ArticleDuring the second day of the 37th Annual J.P. Morgan Healthcare Conference, held January 7-10 in San Francisco, California, Dennis M. Lanfear, president and CEO of Coherus BioSciences, presented an overview of what he called his company’s “branded approach” to selling its newly launched biosimilar pegfilgrastim, Udenyca.